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Abstract Interleukin-11 is a hematopoietic cytokine that
signals via the signal transducer gp130. Although gp130 is
ubiquitously expressed, interleukine-11 responsiveness is re-
stricted to cells that express the interleukine-11 receptor K-
subunit. The interleukine-11 receptor K-subunit can be function-
ally replaced by its soluble form indicating that the transmem-
brane and cytoplasmic parts are not required for signal
transduction. Here, we show that a recombinant fusion protein
of a fragment of the human interleukine-11 receptor K-subunit
ectodomain linked to human interleukine-11 acts as a super-
agonist on cells expressing gp130 but lacking the membrane-
bound interleukine-11 receptor K-subunit. It induces acute phase
protein synthesis in hepatoma cells and efficiently promotes
proliferation of Ba/F3 cells stably, transfected with gp130. In
these bioassays, the fusion protein of a fragment of the human
interleukine-11 receptor K-subunit ectodomain linked to human
interleukine-11 is 50 times more potent than the combination of
interleukine-11 and the soluble interleukine-11 receptor K-
subunit. Thus, our findings support the concept that covalent
fusion of two soluble proteins required for receptor activation
dramatically increases their bioactivity.
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1. Introduction
Interleukin-11 (IL-11) is a hematopoietic cytokine that ex-
erts various biological responses on di¡erent cells and tissues
(for review see [1]). IL-11 acts synergistically with other
growth factors to stimulate various stages of hematopoiesis
both in vitro and in vivo [2^4]. In a phase II clinical trial, it
has been shown that due to its thrombopoietic activity, re-
combinant human IL-11 ameliorates severe chemotherapy-in-
duced thrombocytopenia therefore representing a valuable
therapeutical protein [4]. More recently, anti-in£ammatory
acitivities of IL-11 have been described [5,6]. Female mice
that do not respond to IL-11 due to targeted deletion of a
critical receptor component are infertile as a consequence of
impaired trophoblast implantation [7].
IL-11 belongs to a subfamily of the 4-helix bundle cytokines
including interleukin-6 (IL-6), leukemia inhibitory factor
(LIF), oncostatin M (OSM), ciliary neurotrophic factor
(CNTF) and cardiotrophin-1 (CT-1) that signal via the com-
mon signal transducing receptor protein gp130 (for review see
[8]). IL-11 ¢rst binds to its speci¢c K-receptor subunit (IL-
11R) [9,10] and subsequently, the complex of IL-11 and IL-
11R triggers the dimerization of gp130 [11] leading to activa-
tion of the Janus kinase (Jak)/signal transducer and activator
of transcription (STAT) signal transduction pathway [12].
Both receptor components belong to the family of hemato-
poietic cytokine receptors which are characterized by the pres-
ence of at least one cytokine binding module (CBM) [13]. A
CBM consists of two ¢bronectin type III-like domains. The
N-terminal domain is characterized by four conserved cysteine
residues, the C-terminal domain contains a WSXWS motif.
The extracellular part of the IL-11R is proposed to consist
of an Ig-like domain (D1) followed by a single CBM (D2 and
D3) [9]. Whereas gp130 is expressed ubiquitously [14], IL-11R
expression is more restricted [9,10]. Cells expressing gp130 but
lacking membrane-bound IL-11R can be stimulated by the
combination of IL-11 and soluble IL-11R (sIL-11R) indicat-
ing that the cytoplasmic and transmembrane parts of IL-11R
are not required for signal transduction [15].
In this study, we show that a fusion protein of human IL-11
and a fragment of human sIL-11R acts as a superagonist to
which gp130 expressing cells respond more sensitive than to
the combination of IL-11 and sIL-11R. Superagonistic activ-
ity has also been described for a recombinant fusion protein
consisting of a section of sIL-6R connected to IL-6 by a
polypeptide linker [16]. The covalent linkage of two soluble
receptor activating components exists naturally as well : the
two separately encoded subunits of IL-12 (p35 and p40)
undergo disul¢de-stabilized heterodimerization to constitute
its biologically active form [17]. Our results support the idea
that the covalent linkage of two soluble components required
for receptor activation potentiates their bioactivity.
2. Materials and methods
2.1. Enzymes, antibodies and cell culture
Enzymes were purchased from Boehringer Mannheim (Mannheim,
Germany). The hIL-11 polyclonal antibody used in this study was
obtained from R and D systems (Wiesbaden-Nordenstadt, Germany).
K[32P]dATP was purchased from Amersham International (Amer-
sham, UK) and tran[35S]-label metabolic labelling reagent from ICN
(Meckenheim, Germany). Other chemicals were obtained from Roth
(Karlsruhe, Germany) and media components for the cultivation of
Pichia pastoris were purchased from Sigma-Aldrich (Deisenhofen,
Germany) or Gibco (Eggenstein, Germany). HepG2 cells were main-
tained in DMEM/F12 (Life Technologies, Eggenstein, Germany). Re-
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combinant Trx/IL-11 and sIL-11R were prepared from bacteria or
insect cells, respectively, as described previously [18]. Ba/F3-gp130
cells [19] were cultured in DMEM containing 5% (v/v) conditioned
medium from X63Ag8-653 BPV-mIL-3 myeloma cells (as a source of
IL-3) in the presence of 1 mg/ml G418 in a water-saturated atmos-
phere containing 5% CO2. Both media were supplemented with 10%
(v/v) fetal calf serum, streptomycin (100 Wg/ml) and penicillin (60 Wg/
ml).
2.2. Plasmid construction
First, a section of the hIL-11R cDNA, encoding domains 2 and 3
(amino acids (aa) 109^318), was ampli¢ed by standard PCR methods.
EcoRI/S¢I restriction sites (underlined) were introduced using the
following primer pair: IL-11R-sense 5P-ACTCTCGGATCCCT-
GGGCTACCCTCCAGC-3P and IL-11R-antisense 5P-TGAGAGGG-
CCGGCTGGGCCCCCAGTGCTCGGAGTTCC-3P. Second, a frag-
ment of hIL-11 cDNA encoding the proposed functional part of hIL-
11 (aa 29^199) was ampli¢ed. Asp718/SacII restriction sites were in-
troduced using the following primer pair: IL-11-sense 5P-AGA-
CACGGTACCCCTCGAGTTTCCCCAGAC-3P and IL-11-antisense
5P-ACTGTGCCGCGGTCACAGCCGAGTCTTCAG-3P. The plas-
mid pPICZKA (Invitrogen) for secreted expression of recombinant
proteins in the methylotrophic yeast P. pastoris was digested with
the restriction endonucleases EcoRI and S¢I. Then, the ¢rst amplicon
was ligated (pPICZKA/IL-11R). The resulting plasmid was digested
with Asp718 and SacII and the second amplicon was ligated, which
led to a plasmid encoding both proteins but lacking a peptide linker
(pPICZKA/IL-11R/IL-11). The two following oligonucleotides, encod-
ing the linker sequence, were annealed and subsequently ligated into
the S¢I/Asp718-digested pPICZKA/IL-11R/IL-11 plasmid: linker-
sense 5P-CGGCCAATCAGGAGGTGGAGGAGGCTCCGGAGG-
AGGTTCTGGTGGAGGATCG-3P and linker-antisense 5P-GTAC-
CGATCCTCCACCAGAACCTCCTCCGGAGCCTCCTCCACCT-
CCTGATTGGCCGGCT-3P (pPICZKAIL-11/R-FP). All plasmids
were sequenced using an ABI Prism automated sequencer (Perkin
Elmer).
2.3. Transfection of P. pastoris GS115 and expression of IL-11/R-FP
Competent P. pastoris GS115 were transfected with pPICZKA (con-
trol cells) or with pPICZKAIL-11/R-FP applying the LiCl method
according to the manufacturer’s instructions. Transfected cells were
selected in YPD medium supplied with 0.1 mg/ml zeocin. Before in-
duction of protein synthesis by supplementation of methanol, cells
were grown in standard BMGY medium until A600s 1.5 was reached.
The expression conditions for IL-11/R-FP were optimized in a stand-
ard BMGY medium containing 2% v/v methanol and 1% w/v cas-
amino acids. For protein expression, the GS115 culture was incubated
at 29‡C for 36 h.
2.4. Immunoblotting and enhanced chemiluminescence (ECL) detection
Proteins separated by SDS-PAGE were transferred to a PVDF
membrane by a semi-dry electroblotting procedure. PVDF mem-
branes were blocked in a solution of 20 mM Tris-HCl (pH 7.6), 137
mM NaCl, 0.1% Nonidet-P40 containing 10% bovine serum albumin
and probed with antibody, followed by incubation with horseradish
peroxidase-conjugated secondary antibody. Immunoreactive proteins
were detected by chemiluminescence using the ECL-kit (Amersham,
UK) following the manufacturer’s instructions.
2.5. Induction of K1-antichymotrypsin synthesis in HepG2 cells
HepG2 cells were stimulated with Trx/IL-11 and sIL-11R or IL-11/
R-FP as indicated in Fig. 3. After 18 h, cells were metabolically pulse-
labelled with [35S]methionine/cysteine for 4 h. Induction of K1-anti-
chymotrypsin was measured in cell culture supernatants by immuno-
precipitation. Immunocomplexes were separated on 10% SDS poly-
acrylamide gels, visualized by autoradiography and quanti¢ed using a
Phosphorimager.
2.6. Proliferation assay
Ba/F3-gp130 cells (20 000 cells/well) were plated on 96 well plates
and stimulated as indicated in Fig. 4. After 72 h of incubation, viable
and metabolically active cells were quanti¢ed using a colorimetric
assay based on the Cell Proliferation kit II (XTT) (Boehringer Mann-
heim, Germany).
2.7. Electrophoretic mobility shift assay (EMSA)
Ba/F3-gp130 cells were incubated at 37‡C in the presence of 0.5 nM
IL-11/R-FP or 5 nM of each Trx/IL-11 and sIL-11R for periods of
Fig. 1. Schematic representations of the fusion protein IL-11/R-FP. (A) Schematic representation of the IL-11/R-FP primary structure. The pro-
tein starts with domains 2 and 3 of human IL-11R (Leu-109^Gly-318), followed by a 21 amino acid linker and human IL-11 (Pro-29^Leu-199).
Due to the cloning strategy, the fusion protein contains two additional N-terminal amino acids, shown in italic letters. (B) Schematic represen-
tation of the IL-11/R-FP tertiary structure. The linker (black line) should allow binding of IL-11 to domains 2 (D2) and 3 (D3) of IL-11R. N-
and C-termini are indicated by N and C, respectively.
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time as indicated in Fig. 5. Preparation of nuclear extracts and EM-
SAs were performed as described [20]. A double-stranded oligonucleo-
tide derived from the c-fos promoter (m67SIE: 5P-GGGAGGGATT-
TACGGGGAAATGCTG-3P) was used as 32P-labelled probe [21].
The protein-DNA complexes were separated on a 4.5% polyacryl-
amide gel containing 7.5% glycerol. The electrophoresis was per-
formed using 0.25-fold TBE bu¡er at 260 V.
3. Results
3.1. Expression of IL-11/R-FP in the methylotrophic yeast
P. pastoris
Using a PCR-based methodology, we constructed an ex-
pression vector encoding a fusion protein of the human IL-
11R CBM (domains 2 and 3) and human IL-11. In order to
allow binding of IL-11 to the binding epitope of IL-11R, both
proteins were connected by a £exible polypeptide linker (Fig.
1A). In Fig. 1B, the anticipated ternary structure of the fusion
protein IL-11/R-FP is schematically represented in which the
CBM of IL-11R accommodates IL-11. This arrangement of
the two fusion partners is based on the analogy to the struc-
ture of the growth hormone/growth hormone receptor com-
plex [22]. Similarly, fusion proteins of the two IL-12 subunits
p35 and p40 [23] as well as IL-6 and sIL-6R [16] were con-
structed and shown to be biologically active. The methylotro-
phic yeast P. pastoris was transfected with the vector pPICZ-
KAIL-11/R-FP allowing the expression and secretion of the
fusion protein (for details see Section 2). Supernatants of
mock- or pPICZKAIL-11/R-FP-transfected cells were ana-
lyzed by SDS-PAGE, followed by electroblotting and immu-
nostaining with a hIL-11 polyclonal antibody (Fig. 2). A
prominent band corresponding to a protein of approximately
50 kDa was detected in the IL-11/R-FP supernatants but not
in the supernatants of mock-transfected cells. The electropho-
retic mobility of the 50 kDa protein was increased after pre-
treatment with endoglycosidase H resulting in a 44 kDa pro-
tein. This is in good agreement with the calculated molecular
Fig. 2. Detection of IL-11/R-FP in the supernatants of transfected
yeasts. Supernatants of mock-transfected (control SN) and pPICZ-
KAIL-11/R-FP-transfected yeasts (IL-11/R-FP SN) were concen-
trated, treated with endoglycosidase H as indicated and, after sepa-
ration of proteins on a 10% polyacrylamide SDS gel, analyzed by
immunoblotting using a human IL-11 polyclonal antibody. Electro-
phoretic mobilities of molecular mass marker proteins are indicated
on the left.
Fig. 3. Induction of the K1-ACT synthesis in HepG2 cells. HepG2 cells were stimulated with equilibrated supernatants containing IL-11/R-FP
or the combination of Trx/IL-11 and sIL-11R, each protein at molar concentrations as indicated. Cells incubated with supernatants of mock-
transfected yeast cells served as a control. Newly synthesized proteins were metabolically labelled using [35S]methionine/cysteine. After immuno-
precipitation from cell supernatants and separation by SDS-PAGE, radioactively-labelled K1-ACT was visualized by autoradiography (upper
panel). Quanti¢cation of radioactivity was performed using a Phosphorimager (lower panel). The S.D.s were calculated from two independent
experiments.
FEBS 21942 26-4-99
S. P£anz et al./FEBS Letters 450 (1999) 117^122 119
mass of 43.5 kDa. Thus, the glycoprotein detected by the
antibody can be envisaged as IL-11/R-FP. Band intensities
of IL-11/R-FP and serial dilutions of an IL-11 preparation
of a known concentration were quanti¢ed using a Lumi-Im-
ager (not shown). From these data, the concentration of
IL-11/R-FP in the yeast supernatant was calculated to be
200 ng/ml. Yeast supernatants were equilibrated with PBS
previous to application in the following bioassays.
3.2. IL-11/R-FP e⁄ciently induces acute phase protein
synthesis in hepatoma cells
The combination of IL-11 and sIL-11R induces the acute
phase protein synthesis in hepatoma cells [24]. In order to
evaluate the bioactivity of IL-11/R-FP, HepG2 cells were
stimulated with either the combination of Trx/IL-11 and
sIL-11R or IL-11/R-FP. Supernatants from mock-transfected
cells served as a control. Trx/IL-11 is a well-characterized
recombinant fusion protein of thioredoxin and IL-11 which
has been shown to have biological properties indistinguishable
from IL-11 wild-type [18,25]. After metabolic labelling of the
proteins with [35S]methionine and [35S]cysteine, secreted K1-
antichymotrypsin (K1-ACT) was precipitated from superna-
tants, transferred to SDS-PAGE and quanti¢ed using a Phos-
phorimager (Fig. 3). Whereas no stimulation of the K1-ACT
synthesis was evident at a concentration of 400 pM Trx/IL-11
in the presence of equimolar amounts of sIL-11R, the hepa-
toma cells responded signi¢cantly to 8 pM IL-11/R-FP. Ob-
viously, IL-11/R-FP is a more potent agonist than the combi-
nation of Trx/IL-11 and sIL-11R.
3.3. IL-11/R-FP acts as a superagonist on Ba/F3-gp130 cells
In order to quantify the agonistic activity of IL-11/R-FP
more precisely, proliferation assays were performed. Ba/F3
cells, which normally grow IL-3-dependently, are known to
proliferate in response to various cytokines after transfection
of the corresponding receptor chains. Ba/F3 cells transfected
with gp130 (Ba/F3-gp130) proliferate after stimulation with
Trx/IL-11 and sIL-11R [18]. Half-maximal proliferation was
achieved with 6^7 nM Trx/IL-11 in the presence of equimolar
amounts of sIL-11R (Fig. 4A). When Ba/F3-gp130 cells were
stimulated with IL-11/R-FP, a concentration of 130^140 pM
was su⁄cient for half-maximal proliferation (Fig. 4B). Equil-
ibrated supernatants from mock-transfected yeast cells did
not induce proliferation. Thus, IL-11/R-FP is a 50-fold
more potent agonist compared to the combination of Trx/
IL-11 and sIL-11R. Moreover, an increased sensitivity of
Ba/F3-gp130 cells to IL-11/R-FP cells is obvious from the
response to low concentrations of agonist. Signi¢cant prolif-
eration of Ba/F3-gp130 cells upon incubation with IL-11/R-
FP is observed already at an 80-fold lower concentration
Fig. 4. Proliferation of Ba/F3-gp130 cells. Ba/F3 cells stably trans-
fected with gp130 were seeded in a 96 well plate (20 000 cells/well)
and incubated with increasing amounts of (A) Trx/IL-11 in the pres-
ence of sIL-11R or (B) IL-11/R-FP as indicated in the diagram.
Open circles represent the response of cells stimulated with control
supernatants. After 72 h, a tetrazolium compound was added as a
substrate and incubated for 5 h at 37‡C. Subsequently, the absorb-
ance at 450 and 690 nm was measured. The di¡erence of absorban-
ces corresponds to the number of metabolically active cells (XTT
proliferation assay).
Fig. 5. STAT activation in response to IL-11/R-FP and the combi-
nation of Trx/IL-11 and sIL-11R. Ba/F3-gp130 cells were stimulated
either with IL-11/R-FP (upper panel) at a concentration of 0.5 nM
or the combination of Trx/IL-11 and sIL-11R (lower panel), each at
a concentration of 5 nM. After di¡erent time points (as indicated),
nuclear extracts were prepared and the protein concentrations were
quanti¢ed. 10 Wg of nuclear protein was analyzed by EMSA using a
32P-labelled m67SIE probe derived from the c-fos promotor provid-
ing a binding site for STAT1 and STAT3. Protein-DNA complexes
were separated by PAGE and visualized by autoradiography.
STAT3 and STAT1 homodimers as well as STAT1/3 heterodimers
are indicated by arrows.
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(50 pM) than in response to Trx/IL-11 and sIL-11R (4 nM,
Fig. 4). At high agonist concentrations, both stimuli led to an
almost identical maximal response.
3.4. STAT activation in response to IL-11/R-FP
Signal transduction of IL-11 and related cytokines via the
common signal transducer gp130 is mediated by the activation
of STAT3 and to a lesser extent STAT1 [12,18]. In order to
test in how far STAT activation is a¡ected by fusion of IL-11
to the CBM of its receptor, Ba/F3-gp130 cells were stimulated
either with IL-11/R-FP or the combination of Trx/IL-11 and
sIL-11R. To obtain comparable levels of STAT activation,
IL-11R/FP was applied at a 10-fold lower molar concentra-
tion than Trx/IL-11 and sIL-11R. At di¡erent time points,
nuclear extracts were prepared and analyzed for STAT bind-
ing activity by an EMSA using a radioactively-labelled DNA
probe that contains a binding site for STAT1 and STAT3
homodimers as well as STAT1/STAT3 heterodimers (Fig. 5).
Within a few minutes, both stimuli lead to a strong activation
of STAT3 and to a much lesser extent STAT1 that peaks
within 30 min and again after 4 h. No signi¢cant discrepancies
in the pattern as well as the time course of STAT activation in
response to both stimuli were observed. Thus, superagonism
of IL-11/R-FP is not due to an altered mechanism of STAT
activation.
4. Discussion
In this study, we describe a fusion protein consisting of the
human IL-11R CBM fused by a £exible 21 amino acid linker
to human IL-11. The recombinant fusion protein IL-11/R-FP
was expressed and secreted by the methylotrophic yeast P.
pastoris. Since treatment of the fusion protein with endogly-
cosidase H led to a decrease in the apparent molecular mass,
we conclude that at least one of the two potential N-glycosyl-
ation sites within the CBM of human IL-11R is glycosylated.
In mammalian cells, it has been shown that both sites are used
for N-linked glycosylation [26]. The cytokine itself does not
contain potential N-glycosylation sites [27].
For the related human IL-6R, it has been shown that the
CBM is su⁄cient for ligand binding and mediation of signal
transduction via gp130 [28]. Therefore, IL-11/R-FP was con-
structed without the Ig-like domain of the IL-11R. Our results
demonstrate that in analogy to IL-6R, the Ig-like domain of
IL-11R is not required for biological activity. To obtain su⁄-
cient £exibility, a glycine-rich sequence was chosen to connect
the IL-11R CBM to IL-11. Since the N-terminal 28 amino
acids of IL-6 were found to be dispensable for receptor acti-
vation [29], we fused a truncated IL-11, lacking the sequence
PGPPPGP at its N-terminus. This proline-rich sequence, at
least in Escherichia coli, seems to suppress expression of the
cytokine (unpublished observations). Again, the bioactivity of
IL-11/R-FP in two di¡erent cellular assays proved that this
sequence is indeed not required for functionality.
On HepG2 cells, IL-11/R-FP turned out to be a more po-
tent inducer of the acute phase protein K1-antichymotrypsin
than the combination of IL-11 and sIL-11R. In a proliferation
assay using Ba/F3-gp130 cells, a 50-fold lower concentration
of IL-11/R-FP led to half-maximal stimulation compared to
the two individual components. In line with these ¢ndings is
the observation that a 10-fold higher molar concentration of
IL-11 and sIL-11R is required to obtain an activation of
STAT3 that is comparable to the response to IL-11/R-FP.
Fusion of IL-11 to its K-receptor has no consequence for
the quality of the STAT signal, i.e. the time course of
STAT activation and the ratio of STAT3 and STAT1 activa-
tion suggesting that signaling receptor complexes of similar
conformation are formed in response to both stimuli.
How can the superagonistic activity of IL-11/R-FP be ex-
plained? Receptor activation of gp130 by IL-11 is a two-step
process requiring two binding events with di¡erent a⁄nities.
First, IL-11 binds to either the membrane-bound or the solu-
ble IL-11R with a low a⁄nity. Subsequently, the complex of
IL-11 and IL-11R binds gp130 with a high a⁄nity (KD = 250
pM) [30] leading to gp130 oligomerization and signal trans-
duction. Covalent linkage of IL-11 to IL-11R circumvents the
¢rst low a⁄nity binding step. Thus, the fusion protein IL-11/
R-FP can be envisaged as an activated cytokine that directly
binds its signal transducing receptor gp130 via the high a⁄n-
ity interaction. Since IL-11, due to its hematopoietic and anti-
in£ammatory properties, is of high interest for various medi-
cal applications, this superagonistic fusion protein may be of
great value.
Acknowledgements: This work was supported by Grants from the
European Community (BIO4 CT 972010), the Deutsche Forschungs-
gemeinschaft (Bonn) and the Fonds der Chemischen Industrie (Frank-
furt a. M). The authors thank Stephan Hellwig for helpful discussions.
References
[1] Du, X. and Williams, D.A. (1997) Blood 89, 3897^3908.
[2] Yonemura, Y., Kawakita, M., Masuda, T., Fujimoto, K., Kato,
K. and Takatsuki, K. (1992) Exp. Hematol. 20, 1011.
[3] Neben, S., Donaldson, D., Sie¡, C., Mauch, P., Bodine, D.,
Ferrara, J., Yetz-Aldape, J. and Turner, K. (1994) Exp. Hematol.
22, 353.
[4] Tepler, I. et al. (1996) Blood 87, 3607^3614.
[5] Trepicchio, W.L., Bozza, M., Pedneault, G. and Dorner, A.J.
(1996) J. Immunol. 157, 3627.
[6] Redlich, C.A., Gao, X., Rockwell, S., Kelley, M. and Elias, J.A.
(1996) J. Immunol. 157, 1705.
[7] Robb, L., Li, R., Hartley, L., Nandurkar, H.H., Koentgen, F.
and Begley, C.G. (1998) Nat. Med. 4, 303^308.
[8] Heinrich, P.C., Behrmann, I., Mu«ller-Newen, G., Schaper, F. and
Graeve, L. (1998) Biochem. J. 334, 297^314.
[9] Hilton, D.J. et al. (1994) EMBO J. 13, 4765^4775.
[10] Cherel, M., Sorel, M., Lebeau, B., Dubois, S., Moreau, J.F.,
Bataille, R., Minvielle, S. and Jacques, Y. (1995) Blood 86,
2534^2540.
[11] Yin, T., Taga, T., Tsang, M.L., Yasukawa, K., Kishimoto, T.
and Yang, Y.C. (1993) J. Immunol. 151, 2555^2561.
[12] Lu«tticken, C. et al. (1994) Science 263, 89^92.
[13] Bazan, J.F. (1990) Proc. Natl. Acad. Sci. USA 87, 6934^6938.
[14] Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T. and
Kishimoto, T. (1990) Cell 63, 1149^1157.
[15] Karow, J., Hudson, K.R., Hall, M.A., Vernallis, A.B., Taylor,
J.A., Gossler, A. and Heath, J.K. (1996) Biochem. J. 318, 489^
495.
[16] Fischer, M., Goldschmitt, J., Peschel, C., Brakenho¡, J.P.G.,
Kallen, K.-J., Wollmer, A., Gro«tzinger, J. and Rose-John, S.
(1997) Nat. Biotechnol. 15, 142^145.
[17] Kobayashi, M. et al. (1989) J. Exp. Med 170, 827^845.
[18] Dahmen, H. et al. (1998) Biochem. J. 331, 695^702.
[19] Horsten, U., Mu«ller-Newen, G., Gerhartz, C., Wollmer, A., Wij-
denes, J., Heinrich, P.C. and Gro«tzinger, J. (1997) J. Biol. Chem.
272, 23748^23757.
[20] Wegenka, U.M. et al. (1994) Mol. Cell. Biol. 14, 3186^3196.
[21] Wagner, B.J., Hayes, T.E., Hoban, C.J. and Cochran, B.H.
(1990) EMBO J. 9, 4477^4484.
[22] de Vos, A.M., Ultsch, M. and Kossiako¡, A.A. (1992) Science
255, 306^312.
FEBS 21942 26-4-99
S. P£anz et al./FEBS Letters 450 (1999) 117^122 121
[23] Lieschke, G.J., Rao, P.K., Gately, M.K. and Mulligan, R.C.
(1997) Nat. Biotechnol. 15, 35^40.
[24] Baumann, H., Wang, Y., Morella, K.K., Lai, C.-F., Dams, H.,
Hilton, D.J., Hawley, R.G. and Mackiewicz, A. (1996) J. Immu-
nol. 157, 284^290.
[25] LaVallie, E.R., DiBlasio, E.A., Kovacic, S., Grant, K.L., Schen-
del, P.F. and McCoy, J.M. (1993) Biotechnology 11, 187^193.
[26] Lebeau, B. et al. (1997) FEBS Lett. 407, 141^147.
[27] Paul, S.R. et al. (1990) Proc. Natl. Acad. Sci. USA 87, 7512^
7516.
[28] Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K.,
Matsuda, T., Hirano, T. and Kishimoto, T. (1989) Cell 58,
573^581.
[29] Brakenho¡, J.P.J., Hart, M. and Aarden, L.A. (1989) J. Immu-
nol. 143, 1175^1182.
[30] Nandurkar, H.H., Hilton, D.J., Nathan, P., Wilson, T., Nicola,
N. and Begley, C.G. (1996) Oncogene 12, 585^593.
FEBS 21942 26-4-99
S. P£anz et al./FEBS Letters 450 (1999) 117^122122
